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WHAT IS ALREADY KNOWN ABOUT
THIS SUBJECT
￿ Aspirin and statins are widely-used drugs in
patients with cardiovascular disease.
￿ There is less information on healthy
behaviour vs. drug effects.
WHAT THIS STUDY ADDS
￿ Long-term adherence to aspirin and statin
treatments in patients with established
cardiovascular disease has been
investigated.
￿ Poor health behaviour is not a sufﬁcient
explanation of adverse outcome in poorly
adherent patients.
Aims
To characterize adherence in patients with established cardiovascular
disease taking statins and aspirin and to estimate the effects of adherence
due to health behaviour,a lack of beneﬁcial drug effect,or both on
recurrence of cardiovascular disease or all-cause mortality over 10 years.
Methods
A population-based cohort study using a record-linkage database in
Tayside,Scotland.Subjects with cardiovascular disease (n = 7657;4185
aspirin-alone cohort,671 statin-alone cohort and 2801 combination use
cohort) were studied between 1993 and 2003.The effects of adherence on
recurrence of cardiovascular disease or mortality were assessed using
Poisson regression model.
Results
In subjects taking both aspirin and statins,those adherent to statins but
not aspirin had a lower risk of recurrence [adjusted risk ratio (RR) 0.64;95%
conﬁdence interval 0.49,0.82],but those adherent to aspirin but not statins
has no such effect (adjusted RR 0.91;0.72,1.15),suggesting that adherence
behaviour alone was not responsible for the beneﬁcial effect.Within the
group adherent to aspirin,80% adherence to statins was associated with
reduced recurrence compared with those poorly adherent (adjusted RR
0.76;0.62,0.94),but no such effect of aspirin was seen in those adherent to
statins.Similar results were found for all-cause mortality.
Conclusions
Poor health behaviour is not a sufﬁcient explanation of adverse outcome in
poorly adherent patients.Adverse outcome is more likely to be driven by
foregone drug beneﬁts.
Re-use of this article is permitted in accordance with the Creative Commons Deed,Attribution 2.5,which does not permit commercial exploitation.
British Journal of Clinical
Pharmacology
DOI:10.1111/j.1365-2125.2008.03212.x
110 / Br J Clin Pharmacol / 66:1 / 110–116 © 2008 The Authors
Journal compilation © 2008 Blackwell Publishing Ltd
OnlineOpen: This article is available free online at www.blackwell-synergy.com                             Introduction
Aspirin and statins are widely used drugs in patients with
cardiovascular disease. Large clinical trials have demon-
stratedthebeneﬁtsofthesedrugsoncardiovascularrecur-
rence and mortality. However, the therapeutic effect of a
drug depends not only on patients being prescribed treat-
ment, but also on their being adherent to or compliant
with the treatment. Previous adherence studies have
focused on single drugs and short-term follow up (mostly
1 year) [1–5].These studies have also been confounded
by the notion that adherent subjects may exhibit‘healthy
behaviour’,as was seen in the placebo group of the Coro-
naryDrugProject[6].Thusitisnotknowniftheoutcomeof
poor adherence is secondary to poor health behaviour or
due to the foregone efﬁcacy of prescribed drugs.
This study aimed to investigate the long-term adher-
ence to aspirin and statin treatments in patients with
established cardiovascular disease and to estimate the
effects of adherence on recurrence of cardiovascular
disease or all-cause mortality. In particular, we have
focused on those subjects who exhibited adherence to
one drug (who presumably had good health behaviour)
but not to the other.
Methods
This study was carried out in the population of Tayside in
Scotland, using the Medicine Monitoring Unit’s (MEMO)
record-linkage database [7].The database contains several
datasets,includingalldispensedcommunityprescriptions,
hospital discharge data and other data that are linked by a
unique patient identiﬁer, the community health index
number.The data have been validated and made anony-
mous for the purposes of research as approved by the
government-appointed guardians of patient conﬁdential-
ity.The project was also approved by the Tayside commit-
tee on research medical ethics.
Study population
The study population was the population of Tayside who
were resident and registered with a general practitioner
between January 1993 and December 2003.
Study subjects
The subjects were those who met the entry criteria:
1 Patients who had experienced their ﬁrst cardiovascular
disease hospitalization (angina, myocardial infarction,
heart failure, stroke/transient ischaemic attack and
peripheral vascular disease) between January 1993 and
December 2001. They were identiﬁed from the Tayside
hospital discharge data. Patients who had a hospitaliza-
tion for cardiovascular disease before 1 January 1993
were excluded.The accuracy of diagnosis for these hos-
pital discharge diagnosis data was about 88% [8].
2 Patients who had had at least one prescription for a
statin or aspirin in the period January 1993 to December
2001.Three cohorts (i.e. the statin-alone cohort, aspirin-
alonecohortandthecombinedstatinandaspirincohort
including drug switching users) were identiﬁed from the
dispensed prescribing database.
3 Allsubjectshadatleast180daysoffollow-uptimeinthe
study and at least 28 days’ follow-up time after the ﬁrst
prescription of aspirin or a statin.
Study period
The study period was from January 1993 to December
2003. Patients entered the study at the date of discharge
from hospital. They were followed up for use of statin or
aspirin until December 2001. Cardiovascular disease
recurrence or mortality outcome were followed up until
December 2003.
Statin/aspirin adherence
For each prescription for a statin we knew the strength of
the tablet, the number of tablets dispensed and the
instructions on how these should be taken.Thus the daily
dose and the number of days’ treatment were calculated.
Adherence to statin treatment was calculated as the
number of days with statin supply divided by the total
number of days from the ﬁrst prescription for a statin to
the end of study or the end of 2001.If a patient collected
more drugs than they had been directed to use, the per-
centage of adherence was >100%, but we classiﬁed these
subjects as having maximum adherence.Good adherence
was deﬁned as 80% adherence and partial adherence
wasdeﬁnedas<80%adherence.The80%cut-offpointwas
used because it is used conventionally in clinical trials of
safety and efﬁcacy that have been used to support a new
drug registration [9]. Adherence to aspirin was calculated
in the same way as statin adherence.
Study outcomes
The outcomes of the study were adherence to statin or
aspirin treatment during the follow-up period and cardio-
vascular disease recurrence (deﬁned as hospitalization for
recurrent cardiovascular disease or cardiovascular death)
or all-cause mortality until December 2003.
Statistical analysis
Data were summarized as mean (SD) for continuous vari-
ables and number of subjects (%) for categorical variables.
c
2 and t-tests were performed to determine signiﬁcant dif-
ferences. Cochran–Armitage trend tests were also per-
formed if there were more than two categorical variables.
The Poisson regression model was used to analyse the
timetohospitalizationforrecurrentcardiovasculardisease
or all-cause mortality, giving results in terms of risk ratios
(RR).Analyses were carried out univariately and multivari-
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economic deprivation,calendar year of entry to the study,
presence of diabetes mellitus at baseline (deﬁned as on
antidiabetic treatment), other cardiovascular drug pre-
scriptionsduringthefollow-upincludingangiotensincon-
verting enzyme inhibitors, b-blockers, calcium channel
blockers, anticoagulant, cardiac glycosides, diuretics and
nitrates, and amount of co-prescribing of cardiovascular
drugs. To minimize confounding by the ‘healthy adherer’
effect (i.e.an adherence effect on outcome attributable to
the adoption of healthier lifestyles that accompany adher-
ence behaviours) [2],a prespeciﬁed subgroup analysis was
performed within patients who were on both statins and
aspirin treatments, contrasting those who were adherent
tostatinsbutnotaspirinwiththoseadherenttoaspirinbut
not statins. Interaction between aspirin adherence and
nonsteroidal anti-inﬂammatory drug use during follow-up
was adjusted for in those adherent to statins,as a previous
study has shown that ibuprofen may interact with the car-
dioprotective effects of aspirin [10]. All statistical analyses
were carried out using SAS version 8.0 (SAS Institute,Cary,
NC,USA).
Results
There were 671 patients in the statin-alone cohort,4185 in
the aspirin-alone cohort and 2801 in the combination use
cohort. Figure 1 shows the ﬂow chart of subjects entered
in each cohort.
Drug adherence and characteristics of patients
Table 1 shows the distribution of adherence in the differ-
ent groups. The percentages of good adherence to drug
treatment were 60.0% for the aspirin-alone group, 64.5%
for the statin-alone group and 76% for the combination
use group (P < 0.01) during an average follow-up time of
4.7 years.
Descriptive statistics on adherence levels
The proportion of patients who had good adherence
(80% adherence) in the statin-alone or combination
cohortsdecreasedfromtheendofyear1totheendofyear
8 (Table 2), but was similar in the aspirin-alone cohort.
Table 3 shows the characteristics of patients in the differ-
entadherencegroups.Thereweresigniﬁcantdifferencesin
age and social deprivation between the good adherence
and partial adherence patients. Subjects in the good
adherence group were older and less deprived compared
with the partial adherence group.
Relationship between adherence and
cardiovascular disease recurrence
The effects of adherence to aspirin alone,statin alone and
the combination were assessed for outcome of recurrence
of cardiovascular disease. The number of cardiovascular
events in each group was 2075,166 and 726,respectively.
The rates of events were 53 [95% conﬁdence interval (CI)
45, 60], 112 (95% CI 107, 116) and 14 (95% CI 13, 15) per
1000 person-years, respectively. Table 4 shows the results
of both univariate and multivariate Poisson regression
analysis for recurrence of cardiovascular disease.
There was no signiﬁcant difference in cardiovascular
diseaserecurrencebetweengoodandpartialadherencein
the aspirin-alone group (adjusted RR 1.08, 95% CI 0.97,
1.21).Therewasalowerriskofrecurrenceofcardiovascular
disease in the statin-alone group (adjusted RR 0.66,95% CI
0.47, 0.91). Compared with those who were not adherent
to both statins and aspirin (i.e.statin adherence <80% and
aspirin adherence <80%), patients with 80% adherence
to both statins and aspirin or patients with 80% adher-
ence to statins and <80% adherence to aspirin had a lower
risk of recurrence of cardiovascular disease (adjusted RR
0.69,95% CI 0.56,0.84; and 0.64,95% CI 0.49,0.82,respec-
tively). However, those adherent to aspirin but not to
statins had no such lower risk of cardiovascular disease
recurrence.
To explore the differential effect on cardiovascular
disease recurrence in the combination cohort we
391027
fixed population (1993–2003)
3711
had at least one prescription
of statin between
1993 and 2001
16912
experienced their first cardiovascular disease
7646
had at least one prescription
of aspirin between
1993 and 2001 
671
statin alone  
4185
aspirin alone
2801
combination of statin and aspirin
Figure 1
Flowchart of the patients in the three cohorts
Table 1
Adherence to drug treatment in the different cohorts
Adherence to drug treatment
<80%
n (%)
80%
n (%)
Aspirin-alone cohort 1673 (40.0) 2512 (60.0)
Statin-alone cohort 238 (35.5) 433 (64.5)
Combination use cohort* 464 (24.0) 1471 (76.0)
*Only included patients who had <80% adherence to statins and <80% adher-
ence to aspirin or 80% adherence to aspirin and 80% adherence to statins.
L.Wei et al.
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adherence (Table 5).In those subjects adherent to aspirin,
good adherence to statins predicted a better outcome
(adjusted RR 0.76, 95% CI 0.62, 0.94). However, in subjects
adherent to statins, good adherence to aspirin did not
predict a better outcome (adjusted RR 1.03, 95% CI 0.76,
1.39).
Relationship between adherence and all-cause
mortality
The numbers of deaths during the follow-up were 1293 in
theadherencetoaspirinalonegroup,61inthestatin-alone
group and 222 in the combination group. The mortality
rates were 17 (95% CI 13,21) per 1000 person-years for the
statin-alone group,51 (95% CI 48,54) for the aspirin group
and two (95% CI 2, 3) for the combination use group.The
adjusted RRs for the good adherence group compared
with the partial adherence group were 0.85 (95% CI 0.75,
0.97) for the aspirin-alone group and 0.72 (95% CI 0.42,
1.24) for the statin-alone group.Compared with the group
of <80% adherence for both statins and aspirin, the
adjusted RRs were 0.68 (95% CI 0.57, 0.87) for the group
of 80% adherence to statins and <80% adherence to
aspirin, 0.93 (95% CI 0.73, 1.17) for the group of <80%
adherence to statins and 80% adherence to aspirin and
0.72 (95% CI 0.59,0.88) for the group of 80% adherence
to both statins and aspirin.
Discussion
Our study is the ﬁrst to examine the effects of prolonged
dual adherence to aspirin and statins in patients with car-
diovascular disease in the setting of primary care.Overall,
patients who were taking both treatments had better
adherence than those who were prescribed single drug
treatments. Good adherence was associated with better
outcome in patients who were taking both treatments
when compared with partial adherence.
Adherence to drug treatment
The beneﬁts of cardiovascular disease prevention depend
upon high-risk patients achieving good adherence to
medical regimens of proven efﬁcacy [9].The better adher-
ence found in patients who took both aspirin and statin
treatment may reﬂect disease severity, i.e. patients who
hadmoresevereconditionshadbetteradherencetomedi-
cation than those who had less severe conditions. Adher-
encetostatintreatmentprescribedoutsideofclinicaltrials
is poor [11]. Our study has shown that long-term adher-
ence in cardiovascular patients is suboptimal,especially in
patients who were on single drug treatment.However,the
rates of adherence to statin and aspirin treatment in our
study were higher than in other studies [4, 12–15]. Depri-
vation was also associated with adherence in our study,
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showed that lower socio-economic status was linked to
lower adherence [16].
Effect of adherence on cardiovascular
recurrence or mortality
Previous studies have shown that compliance with cardio-
vascular drug treatment improves outcome [17, 18].
Simpson and colleagues recently conducted a meta-
analysis of the association between adherence to drug
therapy and mortality [19]. However, most studies have
focused on single drug effects. There are no reports of
long-term adherence to combinations of drug treatment.
Table 3
Distribution of characteristics by adherence in the different cohorts
Aspirin alone Statin alone Combination
n = 4185 n = 671 Aspirin (n = 2801) Statin (n = 2801)
<80%
n = 1673
80~100%
n = 2512
<80%
n = 238
80~100%
n = 433
<80%
n = 911
80~100%
n = 1890
<80%
n = 883
80~100%
n = 1918
Sex Male 858 (51.3) 1253 (49.9) 154 (64.7) 251 (58.0) 540 (59.3) 1093 (57.8) 504 (57.1) 1129 (58.9)
Female 815 (48.7) 1259 (50.1) 84 (35.3) 182 (42.0) 371 (40.7) 797 (42.2) 379 (42.9) 789 (41.1)
Age group**
<40 20 (1.2) 14 (0.6) 13 (5.5) 5 (1.2) 22 (2.5) 27 (1.4) 21 (2.3) 28 (1.5)
40–49 97 (5.8) 56 (2.2) 50 (21.0) 71 (16.4) 109 (12.3) 164 (8.6) 129 (14.2) 144 (7.6)
50–59 192 (11.5) 231 (9.2) 86 (36.1) 132 (30.5) 228 (25.8) 475 (24.8) 259 (28.4) 444 (23.5)
60–69 375 (22.4) 535 (21.3) 45 (18.9) 128 (29.5) 283 (33.2) 742 (38.7) 292 (32.1) 743 (39.3)
70–79 523 (31.3) 924 (36.8) 33 (13.9) 80 (18.5) 194 (22.0) 452 (23.6) 182 (20.0) 464 (24.6)
80 466 (27.9) 752 (29.9) 11 (4.6) 17 (3.9) 37 (4.2) 58 (3.0) 28 (3.1) 67 (3.5)
Deprivation category†*
1 least deprived 88 (5.3) 180 (7.2) 19 (8.0) 43 (9.9) 55 (6.2) 132 (6.9) 54 (5.9) 133 (7.0)
2 262 (15.7) 430 (17.2) 44 (18.5) 78 (18.0) 134 (15.2) 333 (17.4) 143 (15.7) 324 (17.2)
3 440 (26.3) 679 (27.1) 52 (21.9) 107 (24.7) 209 (23.7) 485 (25.3) 223 (24.5) 471 (24.9)
4 324 (19.4) 473 (18.9) 36 (15.1) 92 (21.3) 158 (17.9) 383 (20.0) 166 (18.2) 375 (19.9)
5 214 (12.8) 297 (11.9) 32 (13.5) 40 (9.2) 101 (11.5) 200 (10.4) 111 (12.2) 190 (10.1)
6,7 most deprived 343 (20.5) 445 (17.8) 55 (23.1) 73 (16.9) 225 (25.5) 384 (20.0) 213 (23.4) 396 (21.0)
Data are numbers and % unless stated; †excluding missing data. *P < 0.05; **P < 0.01.
Table 4
Univariate and multivariate relative risks for recurrence of cardiovascular
disease in the different cohorts
Outcome predictor
Univariate Multivariate§
RR 95% CI RR 95% CI
Aspirin-alone cohort
Adherence to aspirin (%)
<80 1.00 1.00
80–100 1.14 1.04, 1.24 1.08 0.97, 1.21†
Statin-alone cohort
Adherence to statin (%)
<80 1.00 1.00
80–100 0.83 0.61, 1.12 0.66 0.47, 0.91*
Combination cohort
Adherence to both (%)
Both <80% 1.00 1.00
Statin 80% and aspirin
<80%
0.67* 0.52, 0.86 0.64 0.49, 0.82**
Statin <80% and aspirin
80%
0.93 0.74, 1.18 0.91 0.72, 1.15
Both 80% 0.82* 0.68, 0.99 0.69 0.56, 0.84**
§Adjusted for age, gender, social deprivation, calendar year, diabetes mellitus,
cardiovascular drug use during follow-up and number of cardiovascular prescrip-
tions. †Also adjusted for interaction between aspirin adherence and nonsteroidal
anti-inﬂammatory drug use. *P < 0.05; **P < 0.01.
Table 5
Univariate and multivariate relative risks for recurrence of cardiovascular
disease and all-cause mortality in the good adherence subgroup
Outcome predictor
Univariate Multivariate§
RR 95% CI RR 95% CI
Cardiovascular recurrence
Within statin adherence 80% subgroup
Adherence to aspirin (%)
<80 1.00 1.00
80–100 1.22 0.98, 1.52 1.03 0.76, 1.39†
Within aspirin adherence 80% subgroup
Adherence to statin (%)
<80 1.00 1.00
80–100 0.88 0.72, 1.08 0.76 0.62, 0.94*
All-cause mortality
Within statin adherence 80% subgroup
Adherence to aspirin (%)
<80 1.00 1.00
80–100 1.22 0.80, 1.84 0.73 0.44, 1.22†
Within aspirin adherence 80% subgroup
Adherence to statin (%)
<80 1.00 1.00
80–100 0.80 0.56, 1.15 0.72 0.50, 1.05
§Adjusted for age, gender, social deprivation, calendar year, diabetes mellitus,
cardiovascular drug use during follow-up and number of cardiovascular prescrip-
tions. †Also adjusted for interaction between aspirin adherence and nonsteroidal
anti-inﬂammatory drug use. *P < 0.05; **P < 0.01.
L.Wei et al.
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ence was found in patients who were on both drug treat-
ments and in patients who were taking statin treatment.
Although there was a lower point estimate (0.64 vs. 0.69)
for outcome in patients who were adherent to statin but
not aspirin compared with those who were adherent to
both, the 95% CIs overlapped, and thus this difference
could be due to chance alone.
An important ﬁnding in our study is that we provide
data on the ‘disconnect’ between adherence behaviour
and outcome. Thus, those patients adherent to aspirin
(who presumably had good healthy behaviour) but who
were not adherent to statins had a worse outcome than
those who were adherent to statins. This provides good
evidence that behaviour alone cannot account for these
effects of adherence. Interestingly, in those adherent to
statins,adherencetoaspirinwasnotassociatedwithbetter
outcome.If the better outcome with good adherence was
largely due to behavioural issues then aspirin adherence
wouldbestronglylinkedtogoodoutcome.Inpractice,this
is not the case.There may also be unmeasured confound-
ers that we could not control for in relation to aspirin
adherence and the resulting beneﬁcial effect of aspirin
therapy. Alternatively, reduced adherence may not be as
importantwithaspirintherapy.Forexample,thePhysicians
Health Study detected a beneﬁcial effect of aspirin given
every second day (i.e.50% adherence) [20].
Strengths and limitations
The strengths of the present study are: (i) it was a
population-based cohort design with complete follow-up
over the study period.This approach allowed a‘real-world’
population to be studied representing all socio-economic
groupsandwithinauniversalhealthcarecoveragescheme
[21]. Unlike clinical trials, which focus on highly selected
patients [81–100% men and the young (mean age 55–59
years)][22],population-basedrecord-linkagestudiesallow
real-world populations to be studied. In our study, about
46% of patients were women and the average age of
patients was 67.5 years;(ii) MEMO collects only dispensed
prescribing and so primary noncompliance is eliminated
[23]; (iii) our study shows the details of long-term adher-
ence and its effect on outcome, especially those of con-
comitant drug treatment, whereas other studies have
focused on single drug effects and did not account for
multiple drug effect.
Our study has some limitations. First, MEMO does not
have information on certain risk factors such as lifestyle,
i.e. smoking, alcohol and exercises. These limitations are
not unique to MEMO’s record-linkage database; other
databases also do not have routinely collected informa-
tion on lifestyle or drug indication [24].However,we were
able to adjust for social deprivation, which is a marker of
both poor adherence and poor health behaviour [25].
Second, we may have underestimated the intention-to-
treat with statins and aspirin in the present study, as
adherence to treatment was based on the dispensing of
prescriptions after discharge from hospital. Thus, we
could not distinguish between people who were not
adherent to prescriptions that were written but were not
redeemed at pharmacies, those who had prescriptions
that were written but not collected from the practice and
those who were never prescribed statins. Third, we were
not able to take account of the effect of aspirin that was
purchased over-the-counter (OTC). However, our previous
study [26] has shown that there were hardly any aspirin
prescriptions purchased OTC, and therefore any bias
derived from the OTC would be minimal and would not
be able to change our main results.We assumed that if a
prescription was ﬁlled then patients would adhere to
treatment,but we had no way of knowing whether or not
subjects actually took the pills. However, this problem is
not unique, and in fact this limitation applies to the vast
majority of studies, including randomized controlled
trials.
Inconclusion,patientswhoweretakingbothstatinand
aspirin treatments had better adherence than those who
were on single drug treatment. Good adherence to both
statins and aspirin treatment was associated with lower
risks of recurrence of cardiovascular disease and all-cause
mortality.Although adherence to statins predicted a good
outcome, adherence to aspirin as a group did not.In sub-
jects adherent to one group but not the other, no consis-
tenteffectcompatiblewitha‘healthybehaviour’effectwas
seen, so we conclude that a major component of the
adverse outcome seen with poor adherence are the fore-
gone beneﬁts of drug treatment.
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